Drug Profile
Ocrelizumab - Biogen/Genentech
Alternative Names: 2H7-monoclonal-antibody; 2nd Generation Anti-CD20; Anti-CD20 monoclonal antibody - Genentech; Humanised Anti-CD20 mAb; Monoclonal-antibody-2H7; OCR; OCRE; Ocrevus; Ocrevus SC; PRO 70769; R 1594; RG 1594; rhuMab 2H7; RO4964913Latest Information Update: 22 Apr 2024
Price :
$50
*
At a glance
- Originator Biogen Idec; Genentech
- Developer Biogen; Biogen Idec; Chugai Pharmaceutical; Genentech; Roche
- Class Anti-inflammatories; Antineoplastics; Antirheumatics; Eye disorder therapies; Monoclonal antibodies; Urologics
- Mechanism of Action Antibody-dependent cell cytotoxicity
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Marketed Multiple sclerosis
- Discontinued Eye disorders; Haematological malignancies; Lupus nephritis; Rheumatoid arthritis; Systemic lupus erythematosus
Most Recent Events
- 18 Apr 2024 Long term efficacy and safety data from the phase III OCARINA II trial in Multiple sclerosis released by Genentech
- 17 Apr 2024 Roche expects a decision from the US FDA on supplemental BLA for Multiple sclerosis (SC) in September 2024
- 17 Apr 2024 Roche expects a decision from the EMA on supplemental BLA for Multiple sclerosis (SC) in mid-2024